Jared Moskowitz trades in Abbott Laboratories, AbbVie, and Goldman Sachs stocks

Published 12/02/2025, 10:58
© Reuters.

Jared Moskowitz, the representative for Florida’s 23rd congressional district, has recently made several notable stock transactions, according to the latest Periodic Transaction (JO:TCPJ) Report.

The report indicates that Moskowitz sold stocks in Abbott Laboratories (NYSE:ABT), with each transaction valued between $1,001 and $15,000. These sales were executed on January 15, 2025, and were reported later that month. The stocks were part of the Morgan Stanley (NYSE:MS) Active Assets accounts.

In addition to Abbott Laboratories, Moskowitz also sold his holdings in the Canadian National Railway (TSX:CNR) Company (NYSE:CNI) and Merck (NSE:PROR) & Company, Inc. (NYSE:MRK). Similar to the Abbott Laboratories sales, each transaction was valued between $1,001 and $15,000.

On the other hand, Moskowitz made several purchases as well. He bought stocks in AbbVie Inc . (NYSE:ABBV), Goldman Sachs Group , Inc. (NYSE:GS), McKesson Corporation (NYSE:MCK), and Stryker Corporation (NYSE:SYK). Each of these purchases, like the sales, was valued between $1,001 and $15,000 and were also part of the Morgan Stanley Active Assets accounts.

All transactions were made from Moskowitz’s Morgan Stanley Active Assets accounts, which are based in the US. These accounts include Morgan Stanley Active Assets (1), Morgan Stanley Active Assets (5), and Morgan Stanley Active Assets (6).

The transactions were certified and signed by Moskowitz himself on February 10, 2025. As per the STOCK Act, all members of Congress are required to disclose their transactions to maintain transparency and avoid conflicts of interest.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.